|
Determination of antifungal susceptibility patterns among the clinical isolates of Candida species
Kamiar Zomorodian1, Mohammad Javad Rahimi2, Kayvan Pakshir1, Marjan Motamedi2, Moosa Rahimi Ghiasi2, Hasanein Rezashah3
1 Departments of Medical Mycology and Parasitology, School of Medicine, Shiraz University of Medical Sciences, Shiraz; Center of Basic Researches in Infectious Diseases, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
2 Departments of Medical Mycology and Parasitology, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
3 Center of Basic Researches in Infectious Diseases, School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran
Correspondence Address:
Kamiar Zomorodian
Departments of Medical Mycology and Parasitology, School of Medicine, Shiraz University of Medical Sciences, Shiraz; Center of Basic Researches in Infectious Diseases, School of Medicine, Shiraz University of Medical Sciences, Shiraz
Iran
 Source of Support: Shiraz University of Medical Sciences, Shiraz, Iran. (Grant No.88-5063), Conflict of Interest: None  | Check |
DOI: 10.4103/0974-777X.91059
|
|
Context: Candida species are opportunistic yeasts that cause infections ranging from simple dermatosis to potentially life-threatening fungemia. The emergence of resistance to antifungal drugs has been increased in the past two decades. Aim: the present study we determined to find out the susceptibility profiles of clinical isolates of Candida species against four antifungal drugs, including amphotericin B, ketoconazole, fluconazole and itraconazole. Materials and Methods: Antifungal susceptibility testing of the yeasts was done in accordance with the proposed guidelines for antifungal disk diffusion susceptibility testing of yeasts based on the CLSI document M44-A. Results: A total of 206 yeast isolates were assessed. Among the evaluated Candida species, the highest rates of resistance to ketoconazole were seen in Candida glabrata (16.6%) and Candida albicans (3.2%). Susceptibility and intermediate response to fluconazole were seen in 96.6% and 3.4% of the Candida isolates, respectively. A total of 19 (9.2%) yeast isolates showed petite phenomenon including 11 C. glabrata, 3 C. albicans, 2 Candida dubliniensis and one isolate of each Candida krusei and Candida parapsilosis. Conclusion: The high number of petite mutation in the isolated yeasts should be seriously considered since it may be one of the reasons of antifungal treatment failure. |
